Subscribe

Endometrial Cancer

DUO-E: Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib in Advanced Endometrial Cancer

Does adding durvalumab (a PD-L1 inhibitor) and olaparib (a PARP inhibitor) to standard chemotherapy improve outcomes in advanced or recurrent endometrial cancer?

DESTINY-PanTumor02

Phase II study evaluating the role of HER2-directed ADC Trastuzumab deruxtecan (T-DxD)

Minimally Invasive Surgery in Endometrial Cancer

A systematic review and a meta-analysis supporting the safety of MIS in high-risk endometrial cancer

ASTRO Endometrial Cancer Guidelines 2023

Updated ASTRO guidelines and management of endometrial cancer with radiation therapy